Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor targeted agents matter?
Amanda Pereira-SalgadoAngelyn AntonFanny FranchiniRobert K MaharEdmond M KwanShirley WongJulia ShapiroAndrew WeickhardtArun A AzadLavinia SpainAshray GunjurJavier TorresPhillip ParenteFrancis ParnisJeffrey GohChristopher SteerStephen BrownPeter GibbsBen TranMaarten IJzermanPublished in: Expert review of pharmacoeconomics & outcomes research (2022)
ICERs show ARTA had improved clinical benefit compared to DOC but at higher cost. There were no significant cost differences between combined sequences.